Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Yoshihisa https://orcid.org/0000-0003-2057-408X
Oxnard, Geoffrey R.
Cohen, Elizabeth F.
Mahadevan, Navin R.
Alessi, Joao V.
Hung, Yin P. https://orcid.org/0000-0002-8568-1591
Bertram, Arrien A. https://orcid.org/0000-0001-7237-0623
Heppner, David E. https://orcid.org/0000-0002-0722-5160
Ribeiro, Mauricio F. https://orcid.org/0000-0002-5602-164X
Sacardo, Karina P.
Saddi, Rodrigo https://orcid.org/0000-0002-3005-8188
Macedo, Mariana P. https://orcid.org/0000-0002-0434-7605
Blasco, Rafael B.
Li, Jiaqi
Kurppa, Kari J. https://orcid.org/0000-0001-8286-2429
Nguyen, Tom
Voligny, Emma
Ananda, Guruprasad
Chiarle, Roberto https://orcid.org/0000-0003-1564-8531
Katz, Artur https://orcid.org/0000-0002-1811-1169
Tolstorukov, Michael Y.
Sholl, Lynette M. https://orcid.org/0000-0002-9532-9735
Jänne, Pasi A. https://orcid.org/0000-0002-7821-4928
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 8 September 2022
First Online: 24 September 2022
Competing interests
: G.R.O. reports employment with foundation medicine and equity in Roche. D.E.H. reports consultant fees from Logos Capital. K.P.S. reports consultant fees from Eurofarma. L.M.S. reports consultant fees from EMD Serono, research grant from Genentech, and stock ownership in Moderna. P.A.J. reports consulting fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, Loxo Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Silicon Therapeutics, Nuvalent, Esai, Bayer, and Biocartis; receiving post-marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp; sponsored research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer Ingelheim, Eli Lilly and Company, Revolution Medicines and Astellas Pharmaceuticals; and stock ownership in Loxo Oncology and Gatekeeper Pharmaceuticals. All other authors report no conflicts of interest.
